Literature DB >> 21040717

Chronic infusion of angiotensin receptor antagonists in the hypothalamic paraventricular nucleus prevents hypertension in a rat model of sleep apnea.

Ana Quenia Gomes da Silva1, Marco Antônio Peliky Fontes, Nancy Lapp Kanagy.   

Abstract

Sleep apnea is characterized by increased sympathetic activity and is associated with systemic hypertension. Angiotensin (Ang) peptides have previously been shown to participate in the regulation of sympathetic tone and arterial pressure in the hypothalamic paraventricular nucleus (PVN) neurons. We investigated the role of endogenous Ang peptides within the PVN to control blood pressure in a rat model of sleep apnea-induced hypertension. Male Sprague-Dawley rats (250 g), instrumented with bilateral guide cannulae targeting the PVN, received chronic infusion of Ang antagonists (A-779, Ang-(1-7) antagonist; losartan and ZD7155, AT(1) antagonists; PD123319, AT(2) receptor antagonist, or saline vehicle). A separate group received an infusion of the GABA(A) receptor agonist (muscimol) to inhibit PVN neuronal activity independent of angiotensin receptors. After cannula placement, rats were exposed during their sleep period to eucapnic intermittent hypoxia (IH; nadir 5% O(2); 5% CO(2) to peak 21% O(2); 0% CO(2)) 20 cycles/h, 7 h/day, for 14 days while mean arterial pressure (MAP) was measured by telemetry. In rats receiving saline, IH exposure significantly increased MAP (+12±2 mm Hg vs. Sham -2±1 mm Hg P<0.01). Inhibition of PVN neurons with muscimol reversed the increase in MAP in IH rats (MUS: -9±4 mm Hg vs. vehicle +12±2 mm Hg; P<0.01). Infusion of any of the Ang antagonists also prevented the rise in MAP induced by IH (A-779: -5±1 mm Hg, losartan: -9±4 mm Hg, ZD7155: -11±4 mm Hg and PD123319: -4±3 mm Hg; P<0.01). Our results suggest that endogenous Ang peptides acting in the PVN contribute to IH-induced increases in MAP observed in this rat model of sleep apnea-induced hypertension. Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21040717      PMCID: PMC3018235          DOI: 10.1016/j.brainres.2010.10.087

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  66 in total

1.  AT(1) receptors mediate excitatory inputs to rostral ventrolateral medulla pressor neurons from hypothalamus.

Authors:  T Tagawa; R A Dampney
Journal:  Hypertension       Date:  1999-12       Impact factor: 10.190

Review 2.  Angiotensin and its AT2 receptor: new insights into an old system.

Authors:  M Stoll; T Unger
Journal:  Regul Pept       Date:  2001-06-15

Review 3.  Invited review: Physiological consequences of intermittent hypoxia: systemic blood pressure.

Authors:  E C Fletcher
Journal:  J Appl Physiol (1985)       Date:  2001-04

4.  Involvement of the paraventricular nucleus of the hypothalamus in the pressor response to chemoreflex activation in awake rats.

Authors:  M V Olivan; L G Bonagamba; B H Machado
Journal:  Brain Res       Date:  2001-03-23       Impact factor: 3.252

5.  Exposure to hypoxia produces long-lasting sympathetic activation in humans.

Authors:  A Xie; J B Skatrud; D S Puleo; B J Morgan
Journal:  J Appl Physiol (1985)       Date:  2001-10

6.  Blunted nitric oxide-mediated inhibition of renal nerve discharge within PVN of rats with heart failure.

Authors:  K Zhang; Y F Li; K P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-09       Impact factor: 4.733

7.  Morphological and immunocytochemical characterization of electrophysiologically investigated neurons in the PVN of the rat.

Authors:  M Egli; J P Laurent; R Mosimann; D Felix; H Imboden
Journal:  J Neurosci Methods       Date:  2000-02-15       Impact factor: 2.390

8.  AT(1)-receptor blockade in the hypothalamic PVN reduces central hyperosmolality-induced renal sympathoexcitation.

Authors:  Q H Chen; G M Toney
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-12       Impact factor: 3.619

9.  Differential effects of chronic hypoxia and intermittent hypocapnic and eucapnic hypoxia on pulmonary vasoreactivity.

Authors:  Jessica B Snow; Vanessa Kitzis; Charles E Norton; Samantha N Torres; Kimberly D Johnson; Nancy L Kanagy; Benjimen R Walker; Thomas C Resta
Journal:  J Appl Physiol (1985)       Date:  2007-10-18

10.  Intermittent activation of peripheral chemoreceptors in awake rats induces Fos expression in rostral ventrolateral medulla-projecting neurons in the paraventricular nucleus of the hypothalamus.

Authors:  J C Cruz; L G H Bonagamba; B H Machado; V C Biancardi; J E Stern
Journal:  Neuroscience       Date:  2008-09-11       Impact factor: 3.590

View more
  26 in total

1.  An Essential role for DeltaFosB in the median preoptic nucleus in the sustained hypertensive effects of chronic intermittent hypoxia.

Authors:  J Thomas Cunningham; W David Knight; Steven W Mifflin; Eric J Nestler
Journal:  Hypertension       Date:  2012-06-11       Impact factor: 10.190

Review 2.  Parasympathetic Vagal Control of Cardiac Function.

Authors:  Jhansi Dyavanapalli; Olga Dergacheva; Xin Wang; David Mendelowitz
Journal:  Curr Hypertens Rep       Date:  2016-03       Impact factor: 5.369

Review 3.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Central losartan attenuates increases in arterial pressure and expression of FosB/ΔFosB along the autonomic axis associated with chronic intermittent hypoxia.

Authors:  W David Knight; Ashwini Saxena; Brent Shell; T Prashant Nedungadi; Steven W Mifflin; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-11       Impact factor: 3.619

Review 5.  Neurogenic mechanisms underlying the rapid onset of sympathetic responses to intermittent hypoxia.

Authors:  Steve Mifflin; J Thomas Cunningham; Glenn M Toney
Journal:  J Appl Physiol (1985)       Date:  2015-05-21

6.  Role of angiotensin-converting enzyme 1 within the median preoptic nucleus following chronic intermittent hypoxia.

Authors:  Katelynn Faulk; Brent Shell; T Prashant Nedungadi; J Thomas Cunningham
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-12-21       Impact factor: 3.619

7.  Chronic intermittent hypoxia increases sympathetic control of blood pressure: role of neuronal activity in the hypothalamic paraventricular nucleus.

Authors:  Amanda L Sharpe; Alfredo S Calderon; Mary Ann Andrade; J Thomas Cunningham; Steven W Mifflin; Glenn M Toney
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

8.  Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent.

Authors:  Nicole K Littlejohn; Rick B Siel; Pimonrat Ketsawatsomkron; Christopher J Pelham; Nicole A Pearson; Aline M Hilzendeger; Beth A Buehrer; Benjamin J Weidemann; Huiping Li; Deborah R Davis; Anthony P Thompson; Xuebo Liu; Martin D Cassell; Curt D Sigmund; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-03-27       Impact factor: 3.619

9.  Angiotensin II's role in sodium lactate-induced panic-like responses in rats with repeated urocortin 1 injections into the basolateral amygdala: amygdalar angiotensin receptors and panic.

Authors:  Philip L Johnson; Tammy J Sajdyk; Stephanie D Fitz; Mathew W Hale; Christopher A Lowry; Anders Hay-Schmidt; Anantha Shekhar
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-03-21       Impact factor: 5.067

10.  Rats selectively bred for differences in aerobic capacity have similar hypertensive responses to chronic intermittent hypoxia.

Authors:  Amanda L Sharpe; Mary Ann Andrade; Myrna Herrera-Rosales; Steven L Britton; Lauren G Koch; Glenn M Toney
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-05-24       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.